Clinical Trials

MERCK MK7902-001-01 A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)


Study ID
MERCK MK7902-001-01 Dr. Graham

NCT Number
(Click on the NCT number for more information about the trial)

Research Study Number
Pro2019-0119

Principle Investigator
Dr. Deena Graham

Phase
III

Sponsor
MERCK


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now